Overview
AgomAb Therapeutics was spun out of argenx, Ghent's globally recognized antibody platform company. AgomAb focuses on fibrosis, a condition where scar tissue builds up in organs and progressively impairs their function. There are limited treatment options for fibrosis across its multiple organ manifestations, making it a high-value target for drug development.
The $100M Series C in 2023 is a significant raise that positions AgomAb to advance its pipeline through clinical stages. The argenx lineage provides both scientific credibility and a network of relationships with global pharma partners.
AgomAb is part of the Ghent life sciences cluster, which includes argenx and a growing number of biotech spin-offs benefiting from proximity to Ghent University research.
Funding & milestones
7 events found for AgomAb Therapeutics · 2019–2026
Series AVenture / equity1 sourceEUR 21M
Reported amount EUR 21,000,000
Contemporaneous report gives initial €21m Series A and participating investors; later company extension release corroborates €21m announced in April.
Series a extensionVenture / equity1 sourceAmount not disclosed
Company confirms additional financing from Andera Partners without disclosing extension amount; €21m refers to original April round.
InvestorsAndera PartnersSeries BVenture / equity1 sourceUSD 74M
Reported amount USD 74,000,000
Company-issued Business Wire release syndicated by PharmiWeb states $74m Series B close.
InvestorsV-Bio VenturesRedmile GroupCormorant Asset ManagementAdvent France BiotechnologyAndera PartnersBoehringer Ingelheim Venture FundOmnes CapitalPontifax
Series b extensionVenture / equity1 sourceUSD 40.5M
Reported amount USD 40,500,000
Additional $40.5m close only; stated $114m combined Series B total excluded.
InvestorsPfizerWalleye CapitalAsabys PartnersSeries CVenture / equity1 sourceUSD 100M
Reported amount USD 100,000,000
Dated company PDF confirms $100m Series C close led by Fidelity.
InvestorsFidelity Management & Research CompanyEQT Life SciencesCanaanDawn BiopharmaSeries DVenture / equity1 sourceUSD 89M
Reported amount USD 89,000,000
Company announces $89m financing with new investors Sanofi and Invus alongside existing investors.
InvestorsSanofiInvusPublic listing1 sourceUSD 200M
Reported amount USD 200,000,000
Company SEC-filed release confirms closing 12.5m ADSs at $16 each, $200m gross proceeds; pricing February 5 and listing February 6 are the same IPO.
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Profile narrative
- Series C: $100M2023
- IPO on Nasdaq: $200M raisedFebruary 2026$16/share, valuation approximately $780M, ticker AGMB. Underwriters: JP Morgan, Morgan Stanley. See AgomAb Therapeutics IPO 2026.
Key people
In the news
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.